🫁
Respiratory
Treatments for asthma, COPD, cystic fibrosis, idiopathic pulmonary fibrosis, and other lung diseases.
Companies
0
Pipeline Drugs
296
Key People
378
Respiratory Pipeline (296 drugs)
Approved: 84Commercial: 63Approved/Commercial: 23Phase 3: 22Phase 2: 16Pending Approval: 11Phase 1: 9Phase 1/2: 9Early Phase: 9Preclinical: 6Development: 4Discovery: 4Various: 3Pre-clinical: 3Not Disclosed: 3Phase 2b: 2ANDA Filed/Development: 2Phase 1b/2a: 2Pre-clinical to Phase 3: 2Preclinical/Discovery: 2Phase 1b: 2Phase 2a: 1Phase 3/Commercial: 1Preclinical/Phase 1: 1Approved/Registration: 1Development/Registration: 1Approved/Filed: 1Phase 1b/2: 1Phase 2/3: 1ANDA Filed / Development: 1Filed: 1Phase 1/2a: 1Research: 1Preclinical/Clinical: 1Formulation Development: 1Platform: 1
Key People in Respiratory
PS
Pascal Soriot
Executive Director and Chief Executive Officer
AstraZeneca
JW
Jim Weatherall
Data Science & AI Leadership
AstraZeneca
EW
Emma Walmsley
Chief Executive Officer
GSK plc
IM
Iain Mackay
Chief Financial Officer
GSK plc
TW
Tony Wood
Chief Scientific Officer
GSK plc
DW
Deborah Waterhouse
Chief Executive Officer, Vaccines
GSK plc
LM
Luke Miels
Chief Commercial Officer
GSK plc
KT
Karenann Terrell
Chief Digital and Technology Officer
GSK plc
DC
Diana Conrad
Chief Legal Officer
GSK plc
RS
Regis Simard
President, Pharmaceuticals R&D
GSK plc
RC
Roger Connor
President, Global Affairs
GSK plc
PP
Paul Perreault
Chief Executive Officer and Managing Director
CSL
JL
Joy Linton
Chief Financial Officer
CSL
DB
Dr. Bill Mezzanotte
Chief Medical Officer
CSL
KE
Karen Etchberger
Chief Operating Officer
CSL